CSA Medical, Inc. Receives FDA Breakthrough Device Designation and IDE Approval for its RejuvenAir(R) System for COPD Patients with Chronic Bronchitis

BOSTON, April 3, 2019 -- (Healthcare Sales & Marketing Network) -- CSA Medical today announced that its RejuvenAir® System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA) and received unconditional IDE (Inve... Devices, FDA CSA Medical, Cryospray, RejuvenAir, Chronic Bronchitis, COPD
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news